

include no new matter. Also enclosed is a copy of the NOTICE TO COMPLY.

IN THE SPECIFICATION

On page 17, please replace the paragraph beginning on line 11 with the following:

a₁ In one embodiment, the leucine-based motif is xDxxxLL, SEQID#1, wherein x and may be any amino acids. In another embodiment, the leucine-based motif is xExxxLL, SEQID#2, wherein E is glutamic acid. In another embodiment, the duplet of amino acids may include an isoleucine or a methionine, forming xDxxxLI, SEQID#3 or xDxxxLM, SEQID#4, respectively. Additionally, the aspartic acid, D, may be replaced by a glutamic acid, E, to form xExxxLI, SEQID# 5, and xExxxLM, SEQID#6. In a preferred embodiment, the leucine-based motif is phenylalanine-glutamate-phenylalanine-tyrosine-lycine-leucine-leucine, SEQID #7.


On page 18, replace Table 1 with the following:

<u>Species</u>	<u>Sequence</u>	<u>SEQID#</u>
BoNt/A	FEFYKLL	7
Rat VMAT1	EEKRAIL	8
Rat VMAT 2	EEKMAIL	9
Rat VACHT	SERDVLL	10
Rat d	VDTQVLL	11
Mouse d	AEVQALL	12
Frog g/d	SDKQNLL	13
Chicken g/d	SDRQNLI	14
Sheep d	ADTQVLM	15
Human CD3g	SDKQTLI	16
Human CD4	SQIKRLL	17
Human d	ADTQALL	18

✓ Please enter the attached "Sequence Listing."

Applicant requests early and favorable action in the above-identified application.

Respectfully submitted,



Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
949/450-1750
Facsimilie - 949/450-1764